General Information

Vimpat is an orally-available anticonvulsant. It selectively enhances slow inactivation of sodium channels and interacts with the neuroplasticity-relevant target -collapsin-response mediator protein-2 (CRMP-2).

Vimpat tablets are specifically indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older. Vimpat injection for intravenous use is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older when oral administration is temporarily not feasible.

Vimpat is supplied as a tablet designed for oral administration or as a solution designed for intravenous administration. The recommended initial dose is 50 mg twice daily (100 mg per day). Vimpat can be increased at weekly intervals by 100 mg/day given as two divided doses up to the recommended maintenance dose of 200 to 400 mg/day.

Switching from oral to intravenous dosing
The initial total daily intravenous dosage of Vimpat should be equivalent to the total daily dosage and frequency of oral Vimpat and should be infused intravenously over a period of 30 to 60 minutes.

Switching from intravenous to oral dosing
At the end of the intravenous treatment period, the patient may be switched to Vimpat oral administration at the equivalent daily dosage and frequency of the intravenous administration.

Clinical Results

FDA Approval
The FDA approval of Vimpat was based on the results of three clinical trials. These 12-week, randomized, double-blind, placebo-controlled, multicenter trials enrolled subjects with partial-onset seizures with or without secondary generalization and who were not adequately controlled with 1 to 3 concomitant AEDs. Study 1 compared doses of Vimpat 200 , 400 , and 600 mg/day with placebo. Study 2 compared doses of Vimpat 400 and 600 mg/day with placebo. Study 3 compared doses of Vimpat 200 and 400 mg/day with placebo. Following an 8-week baseline phase to establish baseline seizure frequency prior to randomization, subjects were randomized and titrated to the randomized dose. During the titration phase in all thrree trials, treatment was initiated at 100 mg/day (50 mg given twice daily) and increased in weekly increments of 100 mg/day to the target dose. The Titration Phase lasted 6 weeks in Study 1 and Study 2 and 4 weeks in Study 3. In all three trials, the Titration Phase was followed by a Maintenance Phase that lasted 12 weeks. The primary endpoint was reduction in 28 day seizure frequency (Baseline to Maintenance Phase) as compared to the placebo group. A statistically significant effect was observed with Vimpat treatment at doses of 200 mg/day (Study 3), 400 mg/day (Studies 1, 2, and 3), and 600 mg/day (Studies 1 and 2).

Side Effects

Adverse events associated with the use of Vimpat may include, but are not limited to, the following:

• Dizziness
• Nausea
• Diplopia
• Vision blurred
• Vomiting
• Fatigue
• Ataxia

Mechanism of Action

Vimpat is an orally-available anticonvulsant. It selectively enhances slow inactivation of sodium channels and interacts with the neuroplasticity-relevant target -collapsin-response mediator protein-2 (CRMP-2).

Literature References

Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007 Jul;48(7):1308-17

Stöhr T, Kupferberg HJ, Stables JP, Choi D, Harris RH, Kohn H, Walton N, White HS Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy research 2007 May;74(2-3):147-54

Duncan GE, Kohn H The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model. Epilepsy Research 2005 Oct-Nov;67(1-2):81-7

Additional Information

For additional information regarding Vimpat or partial-onset seizures in epilepsy, please visit the Vimpat web page.